Overview

Gender

male

Investor Type

Angel

Investor Stage

Seed

David is President, CEO, and Director of Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 18 years, leading the last two through successful IPOs and to multi-billion dollar market capitalizations, and raising over $750 million, while generating significant returns for investors.

David was most recently CEO and Co-Founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. David previously co-founded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11 billion and was later sold to Nexprise.

David is Founder and Chairman of the San Francisco-based digital health startup, Farewell, and a Director of the human microbiome company, Epiva.

In 2000, David was named Entrepreneur of the Year in Northern California by Ernst and Young. He holds an M.B.A. from Harvard Business School and a B.S. in chemical engineering from the University of Tulsa. He also attended the United States Air Force Academy, where he was a National Merit Scholar. David serves as a Director of the not-for-profit Infectious Disease Research Institute.

In 1995, Mr. Perry co-founded Virogen, a biotech company based in Boston.

Mr. Perry has a B.S. from the University of Tulsa and an M.B.A. from Harvard Business School.